Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + ketamine + fentanyl
- Development stage
- Unknown
- Lead developer
- Sait Fatih Öner
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This drug combination, specifically referred to as ketofol-fentanyl or Group KP in the SEDCOG clinical trial, is a triple-agent sedoanalgesia regimen consisting of propofol, ketamine, and fentanyl. It was studied by Sait Fatih Öner for use in ambulatory gynecologic surgeries, such as dilatation and curettage. Propofol provides rapid-onset sedation via positive allosteric modulation of the GABA-A receptor. Ketamine acts as a dissociative anesthetic and analgesic through NMDA receptor antagonism, helping to maintain hemodynamic stability and counteract the cardiorespiratory depressive effects of propofol. Fentanyl, a potent synthetic opioid, serves as a mu-opioid receptor agonist to provide deep analgesia. The combination aims to optimize the sedative-analgesic profile while potentially improving early cognitive recovery and hemodynamic parameters compared to dual-agent regimens.
- Other names
- Ketofol-fentanylPropofol-ketamine-fentanyl combinationpropofol + ketamine + fentanyl-Sait Fatih Öner-sedation
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on propofol + ketamine + fentanyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + ketamine + fentanyl.